Trial
NCT02053311
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Prostate Cancer
Intervention
Orteronel
Why stopped
Due to former trials, drug has not demonstrated a clinical profile sufficient to move forward in mCRPC
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-30